Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells

Ovarian cancer accounts for 3% of the total cancers in women, yet it is the fifth leading cause of cancer deaths among women. The BRCA1/2 germline and somatic mutations confer a deficiency of the homologous recombination (HR) repair pathway. Inhibitors of poly (ADP-ribose) polymerase (PARP), another...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Olivia El Naggar, Brenna Doyle, Kelsey Mariner, Susan K. Gilmour
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-05-01
Edice:	Medical Sciences
Témata:	polyamines difluoromethylornithine rucaparib PARP inhibition ovarian cancer
On-line přístup:	https://www.mdpi.com/2076-3271/10/2/28
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!